Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Metastatic Melanoma
100%
Transaminitis
100%
Ipilimumab
100%
Aspartate Aminotransferase
37%
Medical Center
25%
Hepatotoxicity
25%
Routine Care
25%
Mount Sinai
25%
Melanoma Patients
12%
Melanoma
12%
Adverse Events
12%
Hepatitis
12%
Retrospective Review
12%
Alanine Aminotransferase
12%
Dermatitis
12%
Withholding
12%
Randomized Controlled Study
12%
Skin Cancer
12%
First Treatment
12%
Uveitis
12%
National Cancer Institute Common Terminology Criteria for Adverse Events
12%
Thyroiditis
12%
Alanine Aminotransferase Elevation
12%
Novel Immunotherapy
12%
Hypophysitis
12%
Across Population
12%
Immune-related Adverse Events (IrAEs)
12%
Immunosuppressive Medications
12%
Enterocolitis
12%
Nursing and Health Professions
Metastatic Melanoma
100%
Hypertransaminasemia
100%
Ipilimumab
100%
Adverse Event
37%
Food and Drug Administration
37%
Aspartate Aminotransferase
37%
Melanoma
25%
Alanine Aminotransferase
25%
Liver Toxicity
25%
Practice Guideline
12%
National Health Organization
12%
Patient Monitor
12%
Immunotherapy
12%
Uveitis
12%
Immunosuppressive Agent
12%
Skin Cancer
12%
Dermatitis
12%
Hepatitis
12%
Side Effect
12%
Hypophysitis
12%
Thyroiditis
12%
Enterocolitis
12%
Pharmacology, Toxicology and Pharmaceutical Science
Hypertransaminasemia
100%
Metastatic Melanoma
100%
Ipilimumab
100%
Adverse Event
37%
Aspartate Aminotransferase
37%
Melanoma
25%
Hepatotoxicity
25%
Alanine Aminotransferase
25%
Malignant Neoplasm
12%
Clinical Study
12%
Dermatitis
12%
Immunotherapy
12%
Immunosuppressive Agent
12%
Skin Cancer
12%
Thyroiditis
12%
Hepatitis
12%
Uveitis
12%
Enterocolitis
12%
Hypophysitis
12%
Side Effect
12%